Data Bridge
Twenty years of assay, formulation and patient data, locked inside LIMS, ELN, EHR, RDBMS, CSV exports, SAS datasets, EDC and CTMS systems that were never built to talk to AI. We connect it, without replacing the systems it lives in.
The data exists. It just can’t leave the building.
Discovery science generates more evidence than any one lab can use in real time. Almost none of it reaches the systems where AI, regulators or commercial teams could act on it.
Assay and formulation data locked in legacy systems
Decades of screening results, formulation history and study data sit in LIMS, ELN, RDBMS tables, CSV exports, SAS datasets, EDC and CTMS platforms built for storage, not for feeding an AI discovery pipeline.
Discovery outpaces evidence generation
In silico screening can surface thousands of candidate actives or biomarkers in an afternoon; validating them against real historical data still moves at the speed of manual data wrangling.
Regulatory and claims work duplicated by hand
The same assay or trial data gets re-entered, reformatted and re-checked for every dossier, retailer submission or claim substantiation request.
Modernisation looks like a multi-year IT project
Replacing the underlying LIMS, ELN, EHR, RDBMS, EDC or CTMS is expensive and risky, and most R&D and clinical organisations can’t take the system offline to fix it.
An integration layer, not a replacement project
The Data Bridge sits between the legacy systems life-science and health R&D already depend on, and the AI models that need clean, structured, permissioned data to be useful.
Legacy systems
LIMS, ELN, formulation databases, EHR, RDBMS, CSV exports, SAS datasets, EDC and CTMS platforms, years of assay, trial and patient history, left exactly where it lives.
Data Bridge
Secure connection, real-time extraction, field mapping, cleansing and permissioning, feeding structured data into HexisPro.X’s discovery and validation models.
HexisPro.X & AI tools
In silico discovery, assay dashboards, regulatory reporting and claim-substantiation outputs, ready for scientists, clinicians and commercial teams.
The real translation problem
An instrument export means nothing to an AI model until it’s mapped to what a scientist means by it. The bridge does that mapping automatically, at the scale of a full lab archive, not one spreadsheet at a time.
The six layers underneath
Behind the three boxes above is a real architecture, not a single pipeline: the same six-layer structure that underpins AI-guided discovery from target through to real-world evidence.
Every source, untouched. Literature, LIMS/ELN, EHR, genomics and omics, trial records, formulation and adverse-event data, read from where it already lives.
Entities resolved, relationships mapped. Compounds, targets, biomarkers and patients linked into a queryable knowledge graph instead of siloed tables.
Pattern and prediction. NLP over literature and notes, graph learning, biomarker discovery, activity and safety prediction, ingredient or drug repurposing.
Candidate ranking. Disease or claim, mechanism, target, biomarker, compound, scored on efficacy, safety and developability.
Bench and human evidence. Preclinical validation through to trial phases, feeding results straight back into the record.
The loop closes. Real-world outcomes and adverse events re-enter the knowledge graph, re-ranking targets and compounds for the next discovery cycle.
Secure integration with legacy LIMS, ELN, formulation and clinical trial systems, including RDBMS, CSV, SAS, EDC and CTMS platforms, without disrupting instruments and workflows already in place.
Continuous data flow from active studies and screening runs, so new results are available for AI analysis the same day they’re generated.
Instrument and system fields automatically mapped into the scientific concepts a model, or a person, can act on.
Structured outputs into dashboards, regulatory and claims workflows, partner APIs and the tools your teams already use.
What connecting the data actually changes
Figures reflect combined experience from Data Bridge deployments and Hexis Lab’s completed client projects and published research.
Strategic benefits
Real-time dashboards replace manual pulls from lab, clinical and trial systems. Screen candidates computationally before committing laboratory or trial budget. Legacy LIMS, ELN, EHR, RDBMS, EDC and CTMS systems stay operational throughout. Assay and trial data flows straight into substantiation and regulatory workflows.
Financial case
Bridge investment is a fraction of a legacy LIMS/ELN/EHR/EDC/CTMS replacement programme, with time to value measured in months rather than years. Validated actives, mechanisms and biomarkers create licensable, patentable assets, and modernisation can happen one system or one site at a time.
Built for the scale of legacy R&D infrastructure
The same bridge, tuned to how evidence moves through each corner of the life-sciences, health and personal-care landscape, from a national health system’s records to a global pharmaceutical major’s screening archive.
Discovery & mechanism research
AI-guided screening of candidate compounds ahead of bench validation, with mode-of-action data connected to IP and patent filings.
Formulation & claims
Ingredient substitution without losing formulation performance, and independent assay evidence for regulatory and retailer scrutiny.
Clinical evidence & compliance
Automated compilation of assay and study data for dossiers, with audit-ready data lineage from raw result to published claim.
Speed to market
Feasibility, selection and formulation questions answered from one connected data layer, with one integration point instead of three.
Two platforms, one connected pipeline
CTA Solutions brings the integration layer; Hexis Lab brings a decade of AI-guided discovery and laboratory validation.
The data bridge
UK-based, Microsoft Partner. Builds the AI Data Bridge platform that connects legacy infrastructure across finance, retail, telecom and now life sciences, to modern, AI-ready systems.
The discovery & validation layer
Newcastle-based AI ingredient discovery and laboratory validation company, recognised by Frost & Sullivan as a Technology Innovation Leader for ingredients and formulation discovery.
Start with a working session
Bring one legacy system and one evidence question. We’ll map what a connected pipeline looks like for it, and what it would take to stand up.
Hexis Lab Limited
The Biosphere, Draymans Way, Newcastle Helix, Newcastle Upon Tyne NE4 5TG, United Kingdom
info@hexislab.com →CTA Solutions Ltd
264 Brooklands Road, St George’s Place, Weybridge, Surrey KT13 0QX, United Kingdom
info@cta-fintech-solutions.tech →What to bring to the first session
- The name of one legacy system (LIMS, ELN, EHR, RDBMS, CSV export, SAS dataset, EDC or CTMS platform) you’d want connected first.
- One evidence question it currently takes too long to answer.
- Whoever owns that system’s data governance, so scope and permissions can be agreed early.